ECSP19011216A - Inhibidores de piridopyrimdinona cdk2/4/6 - Google Patents
Inhibidores de piridopyrimdinona cdk2/4/6Info
- Publication number
- ECSP19011216A ECSP19011216A ECSENADI201911216A ECDI201911216A ECSP19011216A EC SP19011216 A ECSP19011216 A EC SP19011216A EC SENADI201911216 A ECSENADI201911216 A EC SENADI201911216A EC DI201911216 A ECDI201911216 A EC DI201911216A EC SP19011216 A ECSP19011216 A EC SP19011216A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyridopyrimdinone
- cdk2
- inhibitors
- compounds
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Esta invención se relaciona con compuestos de la Fórmula general (I) (I), y sales farmacéuticamente aceptables de los mismos, en los cuales R1, R2, R¬2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q y r son como se definen en la presente, a composiciones farmacéuticas que comprenden tales compuestos y sales, y métodos para utilizar tales compuestos, sales y composiciones para el tratamiento de crecimiento celular anormal, incluyendo cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662371602P | 2016-08-15 | 2016-08-15 | |
| US201762533347P | 2017-07-17 | 2017-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19011216A true ECSP19011216A (es) | 2019-03-29 |
Family
ID=59631834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201911216A ECSP19011216A (es) | 2016-08-15 | 2019-02-14 | Inhibidores de piridopyrimdinona cdk2/4/6 |
Country Status (43)
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY198534A (en) * | 2016-08-15 | 2023-09-04 | Pfizer | Pyridopyrimdinone cdk2/4/6 inhibitors |
| JP6952747B2 (ja) * | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ |
| JP2020097562A (ja) * | 2018-09-25 | 2020-06-25 | ファイザー・インク | ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オンの合成 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| KR20210107069A (ko) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
| SG11202107225SA (en) * | 2019-01-17 | 2021-08-30 | Pfizer | Crystalline form of a cdk inhibitor |
| PH12021551976A1 (en) * | 2019-02-15 | 2022-07-04 | Incyte Corp | Cyclin-dependent kinase 2 biomarkers and uses thereof |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| US11203594B2 (en) * | 2019-04-19 | 2021-12-21 | Pfizer Inc. | Anti-proliferative agents for treating PAH |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| CA3141452A1 (en) * | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| US20220241412A1 (en) | 2019-05-24 | 2022-08-04 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| WO2021014360A1 (en) | 2019-07-23 | 2021-01-28 | Pfizer Inc. | Oral modified release dosage forms |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
| WO2021073593A1 (zh) * | 2019-10-17 | 2021-04-22 | 南京明德新药研发有限公司 | 作为cdk2/4/6三重抑制剂的氨基嘧啶类化合物 |
| MX2022006578A (es) | 2019-12-17 | 2022-07-04 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos. |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Ｃｄｋ２／４／６阻害剤としての化合物 |
| US12539304B2 (en) * | 2020-03-05 | 2026-02-03 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置 |
| CN113773315A (zh) * | 2020-06-10 | 2021-12-10 | 无锡佰翱得生物科学有限公司 | 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂 |
| CN115702155B (zh) * | 2020-06-17 | 2025-01-24 | 微境生物医药科技(上海)有限公司 | 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 |
| WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
| WO2022018667A1 (en) | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
| DK4214202T3 (da) | 2020-09-15 | 2025-03-31 | Pfizer | Faste former af en cdk4-hæmmer |
| AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
| CA3202355A1 (en) * | 2020-12-22 | 2022-06-30 | Jiping Fu | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022152259A1 (zh) * | 2021-01-15 | 2022-07-21 | 江苏先声药业有限公司 | Cdk2/4/6抑制剂及其制备方法和应用 |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| EP4353724A4 (en) * | 2021-06-09 | 2025-10-08 | Tyk Medicines Zhengzhou Inc | COMPOUND USEFUL AS A CYCLIN-DEPENDENT KINASE INHIBITOR AND USE THEREOF |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023281413A1 (en) | 2021-07-09 | 2023-01-12 | Pfizer Inc. | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |
| CN116390921A (zh) * | 2021-09-29 | 2023-07-04 | 中国医药研究开发中心有限公司 | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
| EP4433061A4 (en) * | 2021-11-18 | 2025-09-03 | Onconova Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
| WO2023141522A2 (en) * | 2022-01-21 | 2023-07-27 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023147372A1 (en) * | 2022-01-25 | 2023-08-03 | Kinnate Biopharma Inc. | Inhibitors of cdk4/6 kinase |
| AU2023289896A1 (en) * | 2022-06-22 | 2024-12-05 | Nikang Therapeutics, Inc. | Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway |
| WO2024039903A2 (en) * | 2022-08-19 | 2024-02-22 | Kymera Therapeutics, Inc. | Cdk2 inhibitors and uses thereof |
| WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
| WO2024173766A1 (en) * | 2023-02-17 | 2024-08-22 | Differentiated Therapeutics, Inc. | Cyclin dependent kinase degraders and methods of use thereof |
| WO2024246285A1 (en) | 2023-06-01 | 2024-12-05 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
| WO2025175258A1 (en) * | 2024-02-17 | 2025-08-21 | Padarn Therapeutics, Inc. | Inhibitors of cdk2 |
| WO2025207957A1 (en) * | 2024-03-28 | 2025-10-02 | Yale University | Small-molecule pi5p4k alpha/beta inhibitors and methods using same |
| CN120842218A (zh) * | 2024-04-26 | 2025-10-28 | 郑州同源康医药有限公司 | 一种嘧啶并氮杂环类化合物的晶型及其制备方法及应用 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| CA2272705C (en) | 1996-11-27 | 2003-03-18 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
| KR20000070751A (ko) | 1997-02-05 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘 |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CN1433417A (zh) * | 2000-01-27 | 2003-07-30 | 沃尼尔·朗伯公司 | 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物 |
| BR0109056A (pt) | 2000-03-06 | 2003-06-03 | Warner Lambert Co | Inibidores da cinase de tirosina de 5-alquilpirido[2,3-d]pirimidinas |
| CN100376571C (zh) | 2001-02-12 | 2008-03-26 | 霍夫曼-拉罗奇有限公司 | 6-取代的吡啶并嘧啶类化合物 |
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| PA8577501A1 (es) * | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| US6951769B2 (en) | 2003-06-04 | 2005-10-04 | Texas Instruments Incorporated | Method for stripping sacrificial layer in MEMS assembly |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| BRPI0507852A (pt) | 2004-02-18 | 2007-07-10 | Warner Lambert Co | 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| US8247408B2 (en) * | 2005-10-07 | 2012-08-21 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer |
| BRPI0617159B8 (pt) * | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo |
| RU2009108006A (ru) | 2006-09-08 | 2010-10-20 | Пфайзер Продактс Инк. (Us) | Синтез 2-(пиридин-2-иламино)-пиридо[2, 3-d]пиримидин-7-онов |
| WO2008032162A1 (en) | 2006-09-15 | 2008-03-20 | Pfizer Products Inc. | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| US8513266B2 (en) * | 2007-04-10 | 2013-08-20 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha |
| CA2719868A1 (en) * | 2008-04-29 | 2009-11-05 | F. Hoffmann-La Roche Ag | Pyrimidinyl pyridone inhibitors of jnk. |
| WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| CA2734037A1 (en) | 2008-10-22 | 2010-04-29 | F. Hoffmann-La Roche Ag | Pyrimidinyl pyridone inhibitors of jnk |
| EP2694504A4 (en) * | 2011-04-08 | 2014-08-27 | Afraxis Holdings Inc | 8-ETHYL-6 (ARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF DISEASES AFFECTING THE NERVOUS SYSTEM AND FOR THE TREATMENT OF CANCER |
| UY34044A (es) * | 2011-04-29 | 2012-11-30 | Sanofi Sa | Metodo de tratamiento contra el linfoma con inhibidores de piridopirimidinona de p13k/mtor |
| TW201306842A (zh) * | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法 |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| US9718821B2 (en) * | 2012-02-23 | 2017-08-01 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| TR201816077T4 (tr) | 2013-02-21 | 2018-11-21 | Pfizer | Seçici bir cdk4/6 inhibitörünün katı formları. |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| WO2015084936A1 (en) * | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US9734210B2 (en) | 2014-07-31 | 2017-08-15 | Linkedin Corporation | Personalized search based on searcher interest |
| CZ201589A3 (cs) * | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| MY198534A (en) * | 2016-08-15 | 2023-09-04 | Pfizer | Pyridopyrimdinone cdk2/4/6 inhibitors |
-
2017
- 2017-07-31 MY MYPI2019000748A patent/MY198534A/en unknown
- 2017-07-31 CR CR20190062A patent/CR20190062A/es unknown
- 2017-07-31 MD MDE20190682T patent/MD3497103T2/ro unknown
- 2017-07-31 AU AU2017311645A patent/AU2017311645B2/en active Active
- 2017-07-31 PL PL17752493T patent/PL3497103T3/pl unknown
- 2017-07-31 JP JP2019507917A patent/JP6563623B1/ja active Active
- 2017-07-31 EP EP17752493.1A patent/EP3497103B1/en active Active
- 2017-07-31 WO PCT/IB2017/054655 patent/WO2018033815A1/en not_active Ceased
- 2017-07-31 ES ES17752493T patent/ES2876411T3/es active Active
- 2017-07-31 CA CA2975033A patent/CA2975033C/en active Active
- 2017-07-31 MX MX2019001849A patent/MX389597B/es unknown
- 2017-07-31 SI SI201730793T patent/SI3497103T1/sl unknown
- 2017-07-31 PT PT177524931T patent/PT3497103T/pt unknown
- 2017-07-31 DK DK17752493.1T patent/DK3497103T3/da active
- 2017-07-31 CN CN202210092651.2A patent/CN114394966B/zh active Active
- 2017-07-31 HR HRP20210871TT patent/HRP20210871T1/hr unknown
- 2017-07-31 CU CU2019000010A patent/CU24522B1/es unknown
- 2017-07-31 SG SG11201900799XA patent/SG11201900799XA/en unknown
- 2017-07-31 GE GEAP201714998A patent/GEP20217234B/en unknown
- 2017-07-31 KR KR1020197007466A patent/KR102236605B1/ko not_active Expired - Fee Related
- 2017-07-31 TN TNP/2019/000039A patent/TN2019000039A1/en unknown
- 2017-07-31 PE PE2019000359A patent/PE20190475A1/es unknown
- 2017-07-31 MA MA45920A patent/MA45920B1/fr unknown
- 2017-07-31 RU RU2019104087A patent/RU2726115C1/ru active
- 2017-07-31 HU HUE17752493A patent/HUE055978T2/hu unknown
- 2017-07-31 CN CN201780063655.5A patent/CN109803968A/zh active Pending
- 2017-07-31 UA UAA201900905A patent/UA124804C2/uk unknown
- 2017-07-31 BR BR112019002610A patent/BR112019002610A2/pt active Search and Examination
- 2017-07-31 NZ NZ750410A patent/NZ750410A/en unknown
- 2017-07-31 RS RS20210691A patent/RS61934B1/sr unknown
- 2017-07-31 LT LTEP17752493.1T patent/LT3497103T/lt unknown
- 2017-07-31 US US15/664,265 patent/US10233188B2/en active Active
- 2017-08-02 TW TW106126113A patent/TWI663169B/zh active
- 2017-08-04 UY UY0001037352A patent/UY37352A/es not_active Application Discontinuation
-
2019
- 2019-01-17 US US16/251,032 patent/US10800783B2/en active Active
- 2019-02-04 ZA ZA2019/00716A patent/ZA201900716B/en unknown
- 2019-02-06 IL IL264687A patent/IL264687B/en active IP Right Grant
- 2019-02-11 NI NI201900013A patent/NI201900013A/es unknown
- 2019-02-12 CL CL2019000368A patent/CL2019000368A1/es unknown
- 2019-02-12 CO CONC2019/0001240A patent/CO2019001240A2/es unknown
- 2019-02-14 EC ECSENADI201911216A patent/ECSP19011216A/es unknown
- 2019-02-14 DO DO2019000030A patent/DOP2019000030A/es unknown
- 2019-02-15 SV SV2019005836A patent/SV2019005836A/es unknown
- 2019-02-15 PH PH12019500329A patent/PH12019500329A1/en unknown
-
2020
- 2020-08-27 US US17/005,233 patent/US11396512B2/en active Active
-
2021
- 2021-06-07 CY CY20211100495T patent/CY1124206T1/el unknown
-
2022
- 2022-06-15 US US17/841,138 patent/US20220324872A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
| CL2020002748A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| UY38553A (es) | Inhibidores de cdk2 | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY38471A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| NI201400107A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| UY37205A (es) | Inhibidores de bromodominios | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| CR20160574A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| MX2016015248A (es) | Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. | |
| MX2019003724A (es) | Oxisteroles sustituidos en c7 y metodos de uso de los mismos. | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| ECSP16074478A (es) | Compuestos novedosos | |
| CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| ECSP18056196A (es) | Derivados de indano | |
| CU20140033A7 (es) | Derivados de pirrolopirimidina y purina | |
| ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida |